Gates Package — page 244

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Christopher Austin, M.D. Director, National Center for Advancing Translational Sciences NIH Stephane Bancel, M.S., M.B.A. Chief Executive Officer Moderna Kara Carter, Ph.D. Senior Vice President, Discovery Biology Dewpoint Therapeutics Marco Cavaleri, Ph.D. Head, Biological Health Threats and Vaccines Strategy European Medicines Agency Tomas Cihlar, Ph.D. Vice President and Head of Virology Gilead Sciences, Inc. Francis Collins, M.D., Ph.D. Director NIH Christine Colvis, Ph.D. Director, Drug Development Partnership Programs National Center for Advancing Translational Sciences, NIH Lawrence Corey, M.D. Professor, Departments of Laboratory Medicine & Medicine Member, Division of Vaccine & Infectious Disease (VIDD), Clinical Research, & Public Health Sciences President & Director Emeritus Fred Hutchinson Cancer Research Center Elizabeth Desrosiers, M.S., P.M.P. Executive Director, Clinical Sciences and Study Management Merck & Co., Inc. Gary Disbrow, Ph.D. Director Biomedical Advanced Research and Development Authority Mikael Dolsten, M.D., Ph.D. Chief Scientific Officer and President, Worldwide Research, Development and Medical Pfizer Ken Duncan, Ph.D. Deputy Director, Discovery -- Therapeutics